Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Spyre Therapeutics (SYRE) Return on Capital Employed: 2016-2025

Historic Return on Capital Employed for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to -0.45%.

  • Spyre Therapeutics' Return on Capital Employed rose 7.00% to -0.45% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.45%, marking a year-over-year increase of 7.00%. This contributed to the annual value of -0.50% for FY2024, which is 89.00% up from last year.
  • Per Spyre Therapeutics' latest filing, its Return on Capital Employed stood at -0.45% for Q3 2025, which was up 0.18% from -0.45% recorded in Q2 2025.
  • Over the past 5 years, Spyre Therapeutics' Return on Capital Employed peaked at 2.56% during Q2 2023, and registered a low of -1.61% during Q1 2023.
  • Over the past 3 years, Spyre Therapeutics' median Return on Capital Employed value was -0.45% (recorded in 2024), while the average stood at -0.42%.
  • Per our database at Business Quant, Spyre Therapeutics' Return on Capital Employed surged by 367bps in 2023 and then crashed by 292bps in 2024.
  • Spyre Therapeutics' Return on Capital Employed (Quarterly) stood at -0.66% in 2021, then slumped by 61bps to -1.27% in 2022, then climbed by 27bps to -1.00% in 2023, then surged by 55bps to -0.45% in 2024, then climbed by 7bps to -0.45% in 2025.
  • Its last three reported values are -0.45% in Q3 2025, -0.45% for Q2 2025, and -0.41% during Q1 2025.